Screener
Allogene Therapeutics ALLO Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $30,309 | $51,688 |
| Short-term investments | 236,577 | 198,522 |
| Prepaid expenses and other current assets | 6,407 | 7,539 |
| Total current assets | 273,293 | 257,749 |
| Long-term investments | — | 8,043 |
| Operating lease right-of-use asset | 38,819 | 39,888 |
| Property and equipment, net | 70,023 | 72,839 |
| Deposit placed in escrow | — | 23,479 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's total current assets?
- Allogene Therapeutics (ALLO) reported total current assets of $273.29M in Q1 2026.
- How has Allogene Therapeutics's total current assets changed year-over-year?
- Allogene Therapeutics's total current assets decreased by 6.3% year-over-year, from $291.58M to $273.29M.
- What is the long-term trend for Allogene Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Allogene Therapeutics's total current assets has grown at a -21.1% compound annual growth rate (CAGR), from $845.13M to $257.75M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Allogene Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude